Last mentioned: Mar 24, 2026
Data Collection Completion
Expected completion of clinical data collection for burn applications.
Regulatory Submission
Target window for potential FDA submission for DeepView System clearance.
Commercial Target
Anticipated focus on commercial scaling and market penetration for DeepView AI.
Clinical Study Expansion
Commencement of expanded clinical validation studies for burn care.
FY 2025 Earnings Release
Company reports $19.7M in total R&D revenue for the full year.
2026 Guidance Introduced
Management provides first-ever revenue guidance for the upcoming fiscal year.
Q4 Earnings Release
Spectral AI reports Q4 revenue beat and introduces 2026 revenue guidance.
BARDA Award
Company receives $31.7 million in non-dilutive funding for the DeepView System.
BARDA Award Announced
Spectral AI receives $31.7 million to accelerate DeepView development.
BARDA Award Announced
Spectral AI receives $31.7M in additional funding for DeepView development.
Clinical Validation Phase
Planned acceleration of clinical trials and R&D activities funded by the award.
Year-End Cash Position
Spectral AI closes the year with $15.4 million in cash and equivalents.
Fiscal Year End
Spectral AI closes FY2025 with $19.7M in R&D revenue and $15.4M in cash.
Spectral AI reported a significant Q4 2025 earnings beat with revenue of $3.8 million and a surprise GAAP profit, bolstered by a recent $31.7 million BARDA award. The company has introduced its first revenue guidance for 2026, marking a critical transition from R&D to commercial-scale medical AI diagnostics.
Spectral AI reported full-year 2025 research and development revenue of $19.7 million, driven by its DeepView AI platform. With a strengthened cash position of $15.4 million, the company has introduced its first revenue guidance for 2026 as it transitions toward commercialization.
Spectral AI has been awarded $31.7 million in additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive capital will support the company's efforts to bring AI-driven diagnostic precision to burn and wound care, particularly for mass casualty scenarios.
Spectral AI has been awarded $31.7 million from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive funding supports the integration of AI-driven predictive analytics into burn and wound care, aiming to improve triage and treatment outcomes in both clinical and emergency response settings.
Spectral AI (NASDAQ: MDAI) has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This AI-powered diagnostic platform aims to provide rapid, accurate assessments of burn wounds and diabetic foot ulcers, potentially transforming emergency and routine wound care.
Spectral AI has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This investment aims to enhance AI-driven medical diagnostics for faster, more accurate wound care decisions, particularly in burn and diabetic foot ulcer management.